<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Trofinetide: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Trofinetide: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Trofinetide: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="140989" href="/d/html/140989.html" rel="external">see "Trofinetide: Drug information"</a> and <a class="drug drug_patient" data-topicid="141010" href="/d/html/141010.html" rel="external">see "Trofinetide: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F58113577"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Daybue</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F57960732"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Glycine-Proline-Glutamate Analogs</span></li></ul></div>
<div class="block dop drugH1Div" id="F57989665"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ddeb7bcc-84fc-472c-a82c-e26af079bb14">Rett syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rett syndrome:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Manufacturer recommends discontinuation of laxatives prior to initiation due to significant incidence of diarrhea in clinical trials.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">9 to &lt;12 kg: Oral: 5,000 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">12 to &lt;20 kg: Oral: 6,000 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">20 to &lt;35 kg: Oral: 8,000 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">35 to &lt;50 kg: Oral: 10,000 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">≥50 kg: Oral: 12,000 mg twice daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Diarrhea, dehydration:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Diarrhea, mild or moderate</i>
<i>: </i>Consider antidiarrheal therapy; monitor hydration status and increase oral fluids as appropriate.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Diarrhea, severe; dehydration</i>
<i>: </i>Interrupt, reduce dose, or discontinue therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">Weight loss, significant: Monitor weight and interrupt, reduce dose, or discontinue therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F57989691"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">Mild kidney impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:6em;">Moderate or severe kidney impairment: Use not recommended; although has not been studied in kidney impairment, trofinetide is eliminated via the kidney.</p></div>
<div class="block dohp drugH1Div" id="F57989697"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; liver metabolism is not a significant route of elimination.</p></div>
<div class="block doa drugH1Div" id="F58019970"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="140989" href="/d/html/140989.html" rel="external">see "Trofinetide: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ddeb7bcc-84fc-472c-a82c-e26af079bb14">Rett syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rett syndrome: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Weight 35 to &lt;50 kg: <b>Oral:</b> 10 g (50 mL) twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Weight ≥50 kg: <b>Oral:</b> 12 g (60 mL) twice daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Missed doses</b>: If a dose is missed or if vomiting occurs after administration, take the next dose as scheduled (eg, do not administer an extra or double dose).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F58019972"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild kidney impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate to severe kidney impairment: Use is not recommended.</p></div>
<div class="block doha drugH1Div" id="F58019973"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, hepatic impairment is not expected to affect trofinetide exposure.</p></div>
<div class="block arsc drugH1Div" id="F58292884"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Gastrointestinal effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal effects, including <b>diarrhea</b>, <b>vomiting</b>, and <b>weight loss,</b> have been frequently reported with trofinetide and may lead to treatment discontinuation. Diarrhea was reported as mild to moderate in a majority of cases; however, persistent diarrhea or recurrence after resolution despite dose interruptions, reductions, or concomitant antidiarrheal therapy has been reported.</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F57967603"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults and pediatrics.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Weight loss (12%; weight loss of &gt;7% from baseline)<span class="lexi-table-link-container"> (<a aria-label="Weight Loss table link" class="lexi-table-link" data-table-id="lexi-content-weight-loss" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-weight-loss')">table 1</a>)</span><span class="table-link" style="display:none;">Weight Loss</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Weight Loss" frame="border" id="lexi-content-weight-loss" rules="all">
<caption style="text-align:center;">
<b>Trofinetide: Adverse Reaction: Weight Loss</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Trofinetide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Trofinetide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children, adolescents, and adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">93</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">94</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Weight loss of &gt;7% from baseline</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (82%)<span class="lexi-table-link-container"> (<a aria-label="Diarrhea table link" class="lexi-table-link" data-table-id="lexi-content-diarrhea" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-diarrhea')">table 2</a>)</span><span class="table-link" style="display:none;">Diarrhea</span>, vomiting (29%)<span class="lexi-table-link-container"> (<a aria-label="Vomiting table link" class="lexi-table-link" data-table-id="lexi-content-vomiting" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-vomiting')">table 3</a>)</span><span class="table-link" style="display:none;">Vomiting</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Diarrhea" frame="border" id="lexi-content-diarrhea" rules="all">
<caption style="text-align:center;">
<b>Trofinetide: Adverse Reaction: Diarrhea</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Trofinetide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Trofinetide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">82%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">20%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children, adolescents, and adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">93</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">94</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Vomiting" frame="border" id="lexi-content-vomiting" rules="all">
<caption style="text-align:center;">
<b>Trofinetide: Adverse Reaction: Vomiting</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Trofinetide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Trofinetide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">29%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children, adolescents, and adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">93</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">94</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Decreased appetite (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety (8%), fatigue (8%), seizure (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasopharyngitis (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (9%)</p></div>
<div class="block coi drugH1Div" id="F57957937"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F58019949"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use is not recommended in patients with moderate to severe renal impairment.</p></div>
<div class="block foc drugH1Div" id="F58113578"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Daybue: 200 mg/mL (450 mL) [contains fd&amp;c red #40 (allura red ac dye), methylparaben sodium, propylparaben sodium; strawberry flavor]</p></div>
<div class="block geq drugH1Div" id="F58113576"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F58262607"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Daybue Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg/mL (per mL): $25.32</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F57989701"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: May administer without regard to food. Administer with a calibrated measuring device (eg, oral syringe or dosing cup); do not use a household measuring device (eg, measuring cup).</p>
<p style="text-indent:-2em;margin-left:4em;">Feeding tube administration: May administer through gastrostomy tube; if administering via gastrojejunal (GJ) tube, administer through G-port.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed dose</i>: If a dose is missed or vomiting occurs after administration, resume dosing at next scheduled time; do not administer an additional dose.</p></div>
<div class="block adm drugH1Div" id="F58019975"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> May administer without regard to food. Administer with a calibrated measuring device (eg, oral syringe or oral dosing cup obtained from pharmacy); do not use a household measuring cup. May also be administered via gastrostomy (G) tube; doses administered via gastrojejunal tubes must be administered through the G port.</p></div>
<div class="block sts drugH1Div" id="F58019951"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store bottle tightly closed and in an upright position at 2°C to 8°C (36°F to 46°F). Do not freeze. Discard any unused oral solution after 14 days of first opening the bottle.</p></div>
<div class="block usep drugH1Div" id="F57958018"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of Rett syndrome (FDA approved in ages ≥2 years and adults).</p></div>
<div class="block cyt drugH1Div" id="F57985084"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F57985081"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors): Trofinetide may increase the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors): Trofinetide may increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).  Management: Avoid concurrent use with OATP1B1/1B3 substrates for which small changes in exposure may be associated with serious toxicities. Monitor for evidence of an altered response to any OATP1B1/1B3 substrate if used together with trofinetide.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F58019947"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events were not observed in animal reproduction studies; studies were conducted using doses lower than the maximum recommended human dose.</p></div>
<div class="block mopp drugH1Div" id="F57989702"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor weight, stool output.</p></div>
<div class="block pha drugH1Div" id="F58019952"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Trofinetide is a synthetic analog of glycine-proline-glutamate, a naturally occurring peptide. The exact mechanism by which trofinetide exerts therapeutic effects is unknown; trofinetide may exhibit anti-inflammatory and trophic effects (Darwish 2022; Glaze 2019).</p></div>
<div class="block phk drugH1Div" id="F57989666"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: ~80 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &lt;6%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Not significantly metabolized via CYP450 enzymes or other hepatic mechanisms of metabolism.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Children ≥5 years and Adolescents ≤15 years: Geometric mean range: 5.3 to 6.1 hours (Glaze 2019); Adults: 1.5 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: ~2 to 3 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~80% as unchanged drug); feces (minor excretion as unchanged drug).</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-35622206">
<a name="35622206"></a>Darwish M, Youakim JM, Harlick J, DeKarske D, Stankovic S. A phase 1, open-label study to evaluate the effects of food and evening dosing on the pharmacokinetics of oral trofinetide in healthy adult subjects.<i> Clin Drug Investig</i>. 2022;42(6):513-524. doi:10.1007/s40261-022-01156-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trofinetide-pediatric-drug-information/abstract-text/35622206/pubmed" id="35622206" target="_blank">35622206</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Daybue (trofinetide) [prescribing information]. San Diego, CA: Acadia Pharmaceuticals Inc; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30918097">
<a name="30918097"></a>Glaze DG, Neul JL, Kaufmann WE, et al. Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome. <i>Neurology</i>. 2019;92(16):e1912-e1925. doi:10.1212/WNL.0000000000007316<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trofinetide-pediatric-drug-information/abstract-text/30918097/pubmed" id="30918097" target="_blank">30918097</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 141002 Version 15.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
